Search results
Results from the WOW.Com Content Network
3D model of 2-Arachidonoylglycerol, an endocannaboid. The endocannabinoid system (ECS) is a biological system composed of endocannabinoids, which are neurotransmitters that bind to cannabinoid receptors, and cannabinoid receptor proteins that are expressed throughout the central nervous system (including the brain) and peripheral nervous system ...
A neurotransmitter for a possible endocannabinoid system in the brain and peripheral nervous system, anandamide (from 'ananda', Sanskrit for 'bliss'), was first characterized in 1992, [18] [19] [20] followed by discovery of other fatty acid neurotransmitters that behave as endogenous cannabinoids having a low-to-high range of efficacy for ...
Mechanism. The CB1 receptor is a pre-synaptic heteroreceptor that modulates neurotransmitter release when activated in a dose-dependent, stereoselective and pertussis toxin -sensitive manner. [14] The CB1 receptor is activated by cannabinoids, generated naturally inside the body (endocannabinoids) or exogenously, normally through cannabis or a ...
A dried cannabis flower. The short-term effects of cannabis are caused by many chemical compounds in the cannabis plant, including 113 [clarification needed] different cannabinoids, such as tetrahydrocannabinol (THC), and 120 terpenes, [1] which allow its drug to have various psychological and physiological effects on the human body.
They are, in effect, released from the postsynaptic cell and act on the presynaptic cell, where the target receptors are densely concentrated on axonal terminals in the zones from which conventional neurotransmitters are released. Activation of cannabinoid receptors temporarily reduces the amount of conventional neurotransmitter released.
Anandamide was discovered by Raphael Mechoulam and fellow coworkers in 1992. This was the first marijuana-like substance produced by the human body to be observed. By examining a pig brain and canine gut, they were able to isolate ANA using mass spectrometry and nuclear magnetic resonance spectroscopy. [7]
Cannabis use disorder (CUD), also known as cannabis addiction or marijuana addiction, is a psychiatric disorder defined in the fifth revision of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) and ICD-10 as the continued use of cannabis despite clinically significant impairment. [2][3]
US: Schedule II as Syndros, and Schedule III as Marinol [2] Schedule I delta-9 tetrahydrocannabinol in pure form. Tetrahydrocannabinol (THC) is a cannabinoid found in cannabis. [9] It is the principal psychoactive constituent of cannabis and one of at least 113 total cannabinoids identified on the plant.